The food-allergy-focused biotech Intrommune Therapeutics is announcing that it is extending the duration of the ongoing Phase 1 OMEGA clinical trial of INT301 in adults with peanut allergy.
The alteration will lengthen the study duration to 48 weeks to include a maintenance period.
The study duration was previously 26 weeks.
The New York City–based company is also amending the study to include a double-blind placebo-controlled oral food challenge (DBPCOFC) at the end of the therapy period.
Get the full story from our sister site, Drug Discovery & Development.